NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 15 hours 5 min ago

Competing Renewal Awards of SBIR Phase IIB Grants for Brain and Behavior Tools (R44 Clinical Trial Optional)

Tue, 01/09/2018 - 02:53
Funding Opportunity PA-18-567 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications that propose to continue the process of developing complex instrumentation, clinical research tools, or behavioral interventions for mental disorders. This FOA specifically invites applications for the competing renewal of previously funded Phase II SBIR grants to further develop the aforementioned types of technologies.
Categories: NIH-Funding

Lab to Marketplace: Tools for Brain and Behavioral Research (R43/R44 - Clinical Trial Optional

Tue, 01/09/2018 - 02:28
Funding Opportunity PAR-18-565 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the translation of technologies for brain or behavioral research from academic and other non-small business research sectors to the marketplace. Encouraged from Small Business Concerns (SBCs) are Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnerships and close collaboration between the original developers of these technologies and SBCs, which may be accomplished in any of a number of ways, including the use of multiple program directors/principal investigators.
Categories: NIH-Funding

NIDCD Research Career Enhancement Award for Established Investigators (K18 -Clinical Trials Required)

Tue, 01/09/2018 - 02:13
Funding Opportunity PAR-18-562 from the NIH Guide for Grants and Contracts. The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-18-NNN
Categories: NIH-Funding

NIDCD Research Career Enhancement Award for Established Investigators (K18 - No Independent Clinical Trials)

Tue, 01/09/2018 - 02:13
Funding Opportunity PAR-18-564 from the NIH Guide for Grants and Contracts. The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Categories: NIH-Funding

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trials Required)

Fri, 01/05/2018 - 13:57
Funding Opportunity PAR-18-560 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials of relevance to the research mission of the National Cancer Institutes (NCI) Division of Cancer Treatment and Diagnosis (DCTD) programs. Applicants are strongly encouraged to consult the DCTD website, https://dctd.cancer.gov/, to learn more about the various program goals, research priorities and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA.
Categories: NIH-Funding

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Fri, 01/05/2018 - 13:57
Funding Opportunity PAR-18-559 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications that include investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and the NCI Division of Cancer Control and Population Sciences as based on their scientific missions. Applications for clinical trials submitted under this FOA should be hypothesis-driven, have clearly described aims and objectives, and have the potential to reduce the burden of cancer through improvements in knowledge, early detection and diagnosis, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to positively impact clinical practice and/or public health.
Categories: NIH-Funding

Notice of Correction for PAR-18-464: Clinical and Translational Science Award (U54 Clinical Trial Optional)

Thu, 01/04/2018 - 12:41
Notice NOT-TR-18-015 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Update: Notice of NIH's Interest in Diversity

Wed, 01/03/2018 - 03:01
Notice NOT-OD-18-122 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NIDCD Clinical Research Center Grant (P50 - Clinical Trials Optional)

Tue, 01/02/2018 - 12:05
Funding Opportunity PAR-18-556 from the NIH Guide for Grants and Contracts. The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Proposal of clinical trial research is allowed but not required (optional) for this FOA
Categories: NIH-Funding

Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01) and Clinical Trial Optional

Tue, 01/02/2018 - 10:44
Funding Opportunity PAR-18-555 from the NIH Guide for Grants and Contracts. A rich body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings suggest that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This funding opportunity supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R01 grant mechanism, whereas its companion funding opportunity seeks shorter, higher-risk R21 grant applications.
Categories: NIH-Funding

Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)

Tue, 01/02/2018 - 10:44
Funding Opportunity PAR-18-554 from the NIH Guide for Grants and Contracts. A rich body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings suggest that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This funding opportunity supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity seeks R01 grant applications.
Categories: NIH-Funding

Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01 - Clinical Trials Optional)

Tue, 01/02/2018 - 09:56
Funding Opportunity PAS-18-557 from the NIH Guide for Grants and Contracts. HIV+ alcohol users remain at high risk for medication non-adherence and rapid disease progression, medication toxicities, organ failure, and poor viremic control, leading to increased risk of transmission and premature death. Recent advances in technology and biomedical science (e.g., new pharmacological agents, alcohol and inflammation biomarkers, internet and mobile technology) open new opportunities for strengthening the quality of HIV/alcohol-related implementation research through utilization of novel technology and biomarkers. This initiative seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Multiple factors need to be investigated, including potentially important patient and provider characteristics, and the organizational, financial, and structural factors that facilitate or inhibit the delivery of evidence-based services for HIV+ individuals with a range of severity of alcohol use problems. The overall goal is to inform clinical decision-making to implement effective interventions that will improve prevention, care, and outcomes across the continuum of HIV and alcohol problem severity and patterns of alcohol use. This solicitation is divided into two major topics. An application may choose to address one or both. These topics include: 1) comparative effectiveness research focused on understanding factors related to early detection, patient engagement and retention in appropriate alcohol and HIV care, and achieving and maintaining optimal treatment responses in diverse settings, and 2) modeling and testing alternative implementation approaches to improve uptake and scaling-up of effective interventions and reduce HIV disease transmission and progression.
Categories: NIH-Funding

Analytical Validation of Candidate Biomarkers for Neurological Disease (U01 Clinical Trial Optional)

Fri, 12/22/2017 - 12:45
Funding Opportunity PAR-18-550 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous analytical validation of candidate biomarker measures or endpoints in a manner that is consistent with FDA guidelines. Analytical validation establishes that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use.
Categories: NIH-Funding

Clinical Validation of a Candidate Biomarker for Neurological Disease (U44 - Clinical Trial Optional)

Fri, 12/22/2017 - 12:44
Funding Opportunity PAR-18-548 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is encourage applications from Small Business Concerns (SBCs) to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of neurological disease for use in multi-site clinical trials and clinical practice.
Categories: NIH-Funding

Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 - Clinical Trial Optional)

Fri, 12/22/2017 - 12:44
Funding Opportunity PAR-18-549 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support applications from Small Business Concerns (SBCs) to perform rigorous analytical validation of candidate biomarker measures or endpoints in a manner that is consistent with FDA guidelines. Analytical validation establishes that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use.
Categories: NIH-Funding

Notice of Pre-Application Webinar for the Common Fund Human Biomolecular Atlas Program (HuBMAP) RFAs (RFA-RM-17-025, RFA-RM-17-027)

Fri, 12/22/2017 - 11:37
Notice NOT-RM-18-008 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Limited Competition: Revision Applications for International Centers of Excellence for Malaria Research (U19 Clinical Trial Optional)

Fri, 12/22/2017 - 11:18
Funding Opportunity RFA-AI-17-044 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit revision applications from currently funded International Centers of Excellence for Malaria Research (ICEMR) investigators. These awards will support the conduct and oversight of observational studies or implementation studies to evaluate the impact of in-country, approved vector control and malaria prevention interventions on the incidence, prevalence, and transmission of malaria. This program will leverage the baseline data, infrastructure, and capacity established by the ICEMRs. The studies will augment or use the established malaria surveillance systems to study the impact of the vector control and malaria prevention interventions on human health outcomes. This FOA solicits three distinct types of studies: Study Type 1 is a Controlled study, Study Type 2 is an Observational study, and Study Type 3 is an Implementation study. Applications may propose projects for one of each Study Type.
Categories: NIH-Funding

Limited Competition: Clinical Research Sites for MACS/WIHS Combined Cohort Study, MACS/WIHS-CCS (U01-Clinical Trials Not Allowed)

Fri, 12/22/2017 - 11:13
Funding Opportunity RFA-HL-19-008 from the NIH Guide for Grants and Contracts. The purpose of this limited competition Funding Opportunity Announcement (FOA) is to advance knowledge of the HIV infection, with a focus on HIV-related comorbidities by supporting current Clinical Research Sites (CRS) of the Multi-Center AIDS Cohort Study (MACS) and the Womens Interagency HIV Study (WIHS) Combined Cohort Study (MACS/WIHS-CCS). Through this FOA each CRS will implement the full MACS/WIHS-CCS unified science agenda and provide expertise to lead part of the unified science agenda (e.g., protocol development, as a reading center, or laboratory). Targeted recruitment will be supported with justification. A companion cooperative agreement will support the MACS/WIHS-CCS Data Analysis and Coordination Center (DACC).
Categories: NIH-Funding

Limited Competition: Data Analysis and Coordination Center for the MACS/WIHS Combined Cohort Study, MACS/WIHS-CCS (U01 Clinical Trials Not Allowed)

Fri, 12/22/2017 - 11:13
Funding Opportunity RFA-HL-19-007 from the NIH Guide for Grants and Contracts. The purpose of this limited competition Funding Opportunity Announcement (FOA) is to support a Data Analysis and Coordination Center (DACC) for the Multicenter AIDS Cohort Study (MACS) and the Womens Interagency HIV Study (WIHS) Combined Cohort Study (MACS/WIHS-CCS). The DACC will work as a member of the MACS/WIHS-CCS consortium to advance knowledge of basic and clinical science, and the epidemiology of HIV infection in the US, with a focus on HIV-related comorbidities. A companion cooperative agreement will support MACS/WIHS-CCS Clinical Research Sites (CRS)
Categories: NIH-Funding